Glycomics is the study of carbohydrates and carbohydrate-containing biomolecules in biological processes. This study is used in diagnostics, drug discovery research, immunology, oncology, and various other applications. Glycomics products are widely used for analysis of cell surface markers, which can act as diagnostic or therapeutic targets.
The global glycobiology market is poised to reach USD 1,211.4 million by 2021 from USD 649.5 million in 2016, at a CAGR of 13.3%. Factors such as increasing government and private funding for glycomics and proteomics research and growing R&D expenditure by pharmaceutical and biotechnology companies are the key drivers for the growth of the market.
Glycobiology is a promising approach to biomarker discovery and validation. The development of various separation techniques coupled with the advanced structure determination capabilities of this field makes possible the separation and identification of thousands of glycans from complex mixtures. Biomarker identification presents significant opportunities for the glycomics market. Glycomics also has a wide range of applications in drug development and enhancement. Glycomics products such as enzymes, kits, and reagents are often used in investigating the role of sugars in the development and progression of diseases like cancer, Alzheimer’s, Parkinson’s, and various infectious diseases like herpes and AIDS.
On the basis of product, the glycobiology market is segmented into enzymes, instruments, kits, and reagents. The enzymes segment is projected to grow at the highest CAGR during the forecast period. This growth is mainly attributed to their consumable nature and wide applications in a variety of R&D and drug discovery procedures. The enzymes segment is further divided into glycosidases, glycosyltransferases, neuraminidases, sialyltransferases, and other enzymes.